How Semaglutide Shortages Have Specifically Affected Diabetes Patients
When GLP-1 supply tightened amid surging weight-management demand, some patients using these drugs for diabetes reported difficulty filling prescriptions.
By the GLP Semaglutide editorial team · Last updated January 10, 2026
Because Ozempic and Wegovy share the same active ingredient and, at points, overlapping supply, a demand surge in one indication (weight management) has been reported to affect availability for patients using the same molecule for its original indication, type 2 diabetes.
Regulatory response
The FDA and Novo Nordisk both issued guidance at various points encouraging prescribers to prioritize patients with an on-label diabetes indication during periods of constrained supply, though implementation varied by pharmacy and region.
Current status
Shortage status is dose-strength-specific and changes over time — the FDA's shortage database is the authoritative source for whether a specific product and strength is currently listed as unavailable.
Primary sources